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OBJECTIVE—Common variants in the melatonin receptor type
1B (MTNR1B) locus have been shown to increase fasting plasma
glucose (FPG) and the risk of type 2 diabetes. The aims of this
study were to evaluate whether nonsynonymous variants in
MTNR1B associate with monogenic forms of hyperglycemia,
type 2 diabetes, or related metabolic traits.
RESEARCH DESIGN AND METHODS—MTNR1B was se-
quenced in 47 probands with clinical maturity-onset diabetes of
the young (MODY), in 51 probands with early-onset familial type
2 diabetes, and in 94 control individuals. Six nonsynonymous
variants (G24E, L60R, V124I, R138C, R231H, and K243R) were
genotyped in up to 22,142 Europeans. Constitutive and melato-
nin-induced signaling was characterized for the wild-type mela-
tonin receptor type 1B (MT2) and the 24E, 60R, and 124I MT2
mutants in transfected COS-7 cells.
RESULTS—No mutations in MTNR1B were MODY speciﬁc, and
none of the investigated MTNR1B variants associated with type
2 diabetes. The common 24E variant associated with increased
prevalence of obesity (odds ratio 1.20 [1.08–1.34]; P  8.3 
10
4) and increased BMI (0.5 kg/m
2; P  1.2  10
5) and
waist circumference (1.2 cm; P  9  10
6) in combined
Danish and French study samples. 24E also associated with
decreased FPG ( 0.08 mmol/l; P  9.2  10
4) in the Danish
Inter99 population. Slightly decreased constitutive activity was
observed for the MT2 24E mutant, while the 124I and 60R
mutants displayed considerably decreased or completely dis-
rupted signaling, respectively.
CONCLUSIONS—Nonsynonymous mutations in MTNR1B are
not a common cause of MODY or type 2 diabetes among Danes.
MTNR1B 24E associates with increased body mass and de-
creased FPG. Decreased MT2 signaling does apparently not
directly associate with FPG or type 2 diabetes. Diabetes 59:
1539–1548, 2010
G
enome-wide association (GWA) studies have
shown that common variation in the melatonin
receptor type 1B (MTNR1B) locus increases
the level of fasting plasma glucose (FPG) and
the risk of type 2 diabetes (1,2). The intronic rs10830963
variant showed the strongest and most independent signal
of association (1,3), and subsequent studies have reported
that carriers of the rs10830963 risk allele have reduced
insulin secretion after both oral and intravenous glucose
challenges (3–5). Thus, it has been proposed that this
common MTNR1B variant increases the risk of type 2
diabetes and impaired fasting glycemia as a result of a
defect of the pancreatic -cells.
The neurohormone melatonin is secreted from the pi-
neal gland during the night and functions as a hormonal
message of the photoperiod. Nocturnal pineal melatonin
secretion is generated by the central clock in the supra-
chiasmatic nucleus, which is entrained by the 24-h light-
darkness cycle (6). Melatonin is particularly involved in
regulation of seasonal and circadian rhythms, such as the
sleep-wake cycle, locomotor activity, feeding, core body
temperature, immune function, and hormone levels (6,7).
Circadian rhythms are highly involved in regulation of a
wide range of physiological processes including metabo-
lism (8), and circadian disturbances including shift work
and sleep disorders increase the risk of both cardiovascu-
lar and metabolic disorders (9,10). Moreover, chronic
sleep deﬁcit is an independent risk factor for obesity (11),
and both circadian rhythms and melatonin secretion are
impaired in type 2 diabetic patients (12). Extrapineal
sources of melatonin secretion have also been described,
e.g., the retina, the pancreas, and the enteroendocrine
cells of the gastrointestinal tract (GI-tract). In these pe-
ripheral tissues, melatonin may have autocrine and para-
crine properties (13,14). Interestingly, the concentration of
melatonin within the gastrointestinal tract is considerably
higher than in plasma, presumably due to release from the
enteroendocrine cells (15,16). This secretion of melatonin
into the gastrointestinal tract is suggested to be related to
food intake and digestion, independently of the photope-
riodic secretion of melatonin from the pineal gland (16,17).
Melatonin mediates its effect through two high-afﬁnity
receptors, the MT1 and MT2 receptors, encoded by
MTNR1A and MTNR1B, respectively (18,19). Both recep-
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G-protein–coupled receptors. In humans, MT2 is expressed
in the suprachiasmatic nucleus and various brain regions
yet also in peripheral tissues, including adipose tissue and
the gastrointestinal tract (20,21). Recently, MTNR1B ex-
pression was also found in human pancreatic islets and in
-cells (2,4,22).
It has been shown that common variants within a gene
can lead to increased risk of type 2 diabetes while rare
coding mutations within the same gene lead to monogenic
forms of diabetes, e.g., maturity-onset diabetes of the
young (MODY) (23). In addition, coding MTNR1B variants
have not yet been reported in relation to metabolism.
Thus, the aims of this study were to evaluate whether
mutations in MTNR1B are responsible for genetically
unexplained MODY subtypes (MODY-X) and to investigate
the inﬂuence of nonsynonymous MTNR1B variants in
relation to type 2 diabetes and related metabolic traits. We
also aimed to determine the functional effect of selected
MTNR1B variants on MT2 receptor signaling.
RESEARCH DESIGN AND METHODS
Detailed characteristics of the screened probands are presented in online
appendix Table 1 (available at http://diabetes.diabetesjournals.org/cgi/
content/full/db09-1757/DC1). Control individuals (n  94) for the mutation
screening were drawn by random from the population-based Inter99 study.
MODY patients. MODY patients (n  47) without mutations in HNF4A,
GCK,o rHNF1A referred to molecular genetic testing were recruited via the
outpatient clinic at Steno Diabetes Center. Inclusion criteria for MODY
families were at least one family member with diagnosis of diabetes before the
age of 25 years and diabetes in two or more consecutive generations. In
addition, the proband should not have been treated with insulin within the ﬁrst
year of diagnosis or should have displayed fasting serum C-peptide 100
pmol/l 1 year after diagnosis. Patients were excluded if they were GAD65
auto-antibody positive.
Early-onset type 2 diabetic patients. Early-onset type 2 diabetic patients
(n  51) were recruited at Steno Diabetes Center. All patients were diagnosed
before the age of 40 years and had a positive family history of type 2 diabetes
in two or more consecutive generations. Patients were excluded if they were
GAD65 auto-antibody positive or if fasting serum C-peptide was 100 pmol/l
at investigation.
Epidemiological studies. Genetic epidemiological studies were performed
in the Danish population-based Inter99 study (n  6,002) (24,25), the Danish
ADDITION screening cohort of individuals at high risk of developing type 2
diabetes (n  8,576) (26), individuals recruited at Steno Diabetes Center (n 
2,293), the French population–based D.E.S.I.R. study (n  4,626) (27,28), and
in a sample of adults from the French Super Obese (FSO) study (29) (n  645).
Detailed descriptions and clinical characteristics of the study populations are
found in appendix Tables 2 and 3.
Case-control studies and quantitative trait analyses. Case-control stud-
ies of type 2 diabetes (n  3,617 case and n  4,975 control subjects) included
all unrelated type 2 diabetic patients (n  328) and glucose-tolerant control
individuals (n  4,460) from the Inter99 study, type 2 diabetic patients from
the Danish ADDITION intervention study (n  1,617), and individuals
recruited from the outpatient clinic at Steno Diabetes Center (n  1,672 case
and n  515 control subjects). Normal glucose tolerance and type 2 diabetes
were deﬁned according to the World Health Organization 1999 criteria (30),
and all control individuals had normal fasting glycaemia and were normal
glucose tolerant following a 75-g oral glucose tolerance test (OGTT).
Patients treated for type 2 diabetes were not included in obesity case-
control studies or in quantitative trait analyses. Danish case-control studies of
obesity included up to 6,828 individuals, comprising 2,608 normal-weight (BMI
25 kg/m
2) and 971 obese (BMI 30 kg/m
2) individuals from the Inter99
study, up to 2,881 obese individuals from the Danish ADDITION screening
cohort, and 272 normal-weight and 96 obese individuals from Steno Diabetes
Center. French case-control studies of obesity (n  3,773) included individ-
uals from the population-based D.E.S.I.R. study (normal weight, n  2,738;
obese, n  390) and obese individuals from the FSO study (n  645).
Quantitative analyses of BMI and waist circumference were performed in
individuals from the Danish population-based Inter99 study sample (n 
5,885). Potential associations with BMI and waist circumference for G24E,
L60R, and V124I were evaluated in the French population–based D.E.S.I.R.
study sample (n  4,626) and in nonpopulation-based study samples: the
Danish ADDITION screening cohort (n  8,576), samples collected at Steno
Diabetes Center (n  649), and adults from the FSO study (n  645). Analyses
of biochemical variables obtained during an OGTT were performed in
individuals from the Danish population-based Inter99 study. All study partic-
ipants were unrelated and Danish or French by self-report. Informed written
consent was obtained from all individuals before participation. The studies
were approved by the regional ethical committees and were in accordance
with the principles of the Declaration of Helsinki II.
Sequencing. MTNR1B was divided into four segments covering the two
exons, exon-intron boundaries, and untranslated regions (UTRs). The seg-
ments were ampliﬁed by standard PCR and sequenced directly by the Sanger
sequencing method. All primers were designed with Primer3 (http://frodo.wi.
mit.edu/). The sequences were analyzed on a 3130XL genetic analyzer (Ap-
plied Biosystems), and mutations were detected with SeqScape v2.5 (Applied
Biosystems). Details of primers and PCR conditions are provided in online
appendix Table 4. DNA was puriﬁed from leukocytes obtained from blood
samples.
Genotyping. Genotyping was performed by KASPa (KBioscience, Hoddes-
don).Genotype success rates were 96%, and concordance between 513
duplicate samples was 99%. Genotypes obeyed Hardy-Weinberg equilibrium
in all study populations (P  0.01). For rare variants with minor allele
frequencies (MAFs) 0.5% (L60R, V124I, and R138C), mutation carriers and
noncalled samples, selected by visual inspection of the genotype plots, were
evaluated by direct sequencing according to the mutation detection protocol.
No additional carriers were found by resequencing of 384 randomly selected
samples. DNA was puriﬁed from leukocytes obtained from blood samples.
Statistical analyses. The statistical analyses were performed using RGui,
version 2.8.1 (http://www.r-project.org). A P value of 0.05 was considered
signiﬁcant. Results are reported uncorrected for multiple testing. Statistical
analyses were calculated assuming an additive (rs8192552 [G24E]) or domi-
nant (L60R, V124I, rs8192553 [R231H], rs61746674 [R138C], and rs61747139
[K243R]) genetic model. Logistic regression was applied to test for differences
in genotype distribution in case-control studies, and linear regression was
applied to test quantitative variables for differences between genotype groups.
Effect sizes are given as actual values or percentage if the trait was
logarithmically transformed. The combined Danish and French case-control
studies of obesity and quantitative analyses of BMI and waist circumference
were performed assuming a ﬁxed effect while adjusting for nationality (Danish
or French) as a factor. All analyses were adjusted for sex and age. Conditional
analyses were performed by comparing a model including one variant with an
alternative model including two variants adjusted for age, sex, and BMI. In the
type 2 diabetes case-control studies, we had 80% statistical power to detect
an odds ratio (OR) of 1.65, 1.45, and 1.20, assuming MAFs of 0.5, 1, and 5%,
respectively.
MT2 receptor signaling. Mutations were constructed for G24E, L60R, and
V124I by PCR using the overlap extension method as previously described
(31). The PCR products were digested, puriﬁed, and cloned into the pCMV-
Tag(2B) vector. All mutations were veriﬁed by restriction endonuclease
mapping and subsequent DNA sequence analysis using an ABI 310 automated
sequencer. COS-7 cells were grown in Dulbecco’s modiﬁed Eagle’s medium
1885 supplemented with 10% FCS, 2 mmol/l glutamine, and 0.01 mg/ml
gentamicin. Cells were transfected with 10 g cDNA of wild-type or mutant
MT2 receptors and 10 g cDNA of a G	6qi4myr (32) using the calcium
phosphate precipitation method with chloroquine addition. The chimeric
G-protein allows the Gi-coupled receptors to signal through the signal
transduction pathways known for the Gq-coupled receptors (32).
One day after transfection, COS-7 cells were incubated for 24 h with 5
Ci of [
3H]-myo-inositol (PT6-271; Amersham) in 1 ml medium, washed
twice in buffer (20 mmol/l HEPES [pH 7.4]), and were subsequently
incubated in 0.5 ml buffer supplemented with 10 mmol/l LiCl at 37°C for 30
min. After stimulation with various concentrations of melatonin for 45 min
at 37°C, cells were extracted with 10% ice-cold formic acid followed by
incubation on ice for 30 min. The generated [
3H]-inositol phosphate was
puriﬁed on Bio-Rad AG 1-X8 anion-exchange resins. All experiments were
done in duplicates and repeated three times. Comparisons at each concen-
tration point of melatonin between wild-type and mutant receptors were
made by unpaired t tests.
RESULTS
Mutation detection. Table 1 and Fig. 1 show a summary
of all variants identiﬁed in the mutation screening. No
novel MTNR1B mutations were found in the 47 MODY-X
probands. One novel nonsynonymous mutation, V124I,
was found in an early-onset type 2 diabetic patient. One
novel synonymous variant, I48I, and one novel 3
UTR
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(dbSNP build 129), were also observed in the screened
probands. Four known variants—rs8192552 (G24E),
rs61746674 (R138C), rs8192553 (R231H), and rs61747139
(K243R)—changed an amino acid in the protein. In addi-
tion, three novel mutations, A13V, A13E, and exon 2 
107GT, were identiﬁed in three unrelated glucose-toler-
ant individuals but were not observed in any of the
diabetic probands. The previously described L60R muta-
tion was not observed in this screening but was included
in the present study because of a reported prevalence of
0.4% in the French population (2). Since no mutations
were familyspeciﬁc, we did not test for cosegregation in
the families.
Epidemiological studies. Six nonsynonymous variants
(L60R, V124I, rs8192552 [G24E], rs61746674 [R138C],
rs8192553 [R231H], and rs61747139 [K243R]) were initially
genotyped in the population-based Inter99 population
(n  6,002), screen-detected type 2 diabetic individuals
from the Danish ADDITION study (n  1,617), and addi-
tional nondiabetic individuals (n  621) and type 2 dia-
betic patients (n  1,672) recruited from the Steno
outpatient clinic. MAFs in the Danish population (n 
9,912) are shown in Table 1.
Case-control studies of type 2 diabetes and obesity.
Potential associations with susceptibility to type 2 diabe-
tes were evaluated in Danish case-control studies (n 
8,592) (Table 2). The investigated MTNR1B nonsynony-
mous variants did not associate with type 2 diabetes
(Table 2) and also did not after the analyses were adjusted
for BMI (data not shown).
Potential associations with susceptibility to obesity
were evaluated in Danish (up to 6,828 subjects) and
French (n  3,773) case-control studies. Codons 24E and
124I were initially associated with increased risk of obe-
sity (G24E per allele OR 1.27 [95% CI 1.08–1.48], P  0.003;
V124I 2.17 [1.01–4.67], P  0.05) in a Danish case-control
study (n  4,837). No obese individuals were carriers of
L60R, and no associations with obesity were observed for
R138C, R231H, or K243R (Table 3). Following genotyping
of additional Danish obese case subjects (n  1,991), the
association between G24E and obesity remained signiﬁ-
cant in Danish analyses (1.21 [1.05–1.39), P  0.008)
(Table 3). In a French case-control study, 24E similarly
associated with increased risk of obesity (1.21 [1.00–1.46],
P  0.05) (Table 3), and in combined analyses of Danish
and French individuals the association was substantiated
(1.20 [1.08–1.34], P  8  10
4) (Table 3). When these
analyses were restricted to the population-based samples
Inter99 and D.E.S.I.R., results were similar (Inter99 1.37
[1.15–1.64], P  5  10
4; D.E.S.I.R. 1.48 [1.13–1.93], P 
0.004; and combined 1.40 [1.21–1.43], P  9  10
6).
Following additional genotyping, L60R and V124I did not
associate with obesity in Danish, French, or combined
study samples (Table 3).
Quantitative analyses of BMI and waist circumfer-
ence. Quantitative analyses of BMI and waist circumfer-
ence were performed in the Danish population–based
Inter99 study sample (n  5,885) (Table 4). Associations
for G24E, L60R, and V124I were evaluated in the French
D.E.S.I.R. population-based study sample (n  4,626)
(Table 4), as well as in nonpopulation-based samples, i.e.,
Danish ADDITION screening cohort (n  8,576), samples
collected at Steno Diabetes Center (n  649), and FSO
adults (n  645) (online appendix Table 7).
Codon 24E associated with a dose-dependent increase
in BMI (0.5 kg/m
2 [0.2–0.7], P  0.002) and waist
circumference (1.1 cm [0.4–1.8], P  0.003) in the
Danish Inter99 population (Table 4). In the French D.E.S.I.R.
population-based study sample, similar associations were
observed between 24E and increased BMI (0.5 kg/m2
[0.2–0.7], P  0.001) and waist circumference (1.3 cm
[0.6–2.0], P  4  10
4) (Table 4). In combined Danish and
French population–based analyses, the ﬁndings were sub-
stantiated (BMI 0.5 kg/m
2 [0.3–0.7], P  1  10
5;
waist 1.2 cm [0.7–1.7], P  9  10
6) (Table 4).
However, G24E did not show any signiﬁcant associations
with BMI and waist circumference in non–population-
based study samples, i.e., the Danish ADDITION screening
cohort, the samples collected at Steno Diabetes Center,
and FSO adults (online appendix Table 7).
L60R was found in only four individuals from the Inter99
TABLE 1
MAFs of MTNR1B variants identiﬁed from sequencing of Danish probands from MODY families and families with early-onset type 2
diabetes
rs Variant Position
MAFs
MODY
(n  47)
Early-onset type 2
diabetes (n  51)
Controls
(n  94)
Genotyping
(n  9,912)
Novel c.38CT, p.13AV 92,342,570 (exon 1) 0 0 0.005 –
Novel c.38CA, p.13AE 92,342,570 (exon 1) 0 0 0.005 –
rs8192552 c.71GA, p.24GE 92,342,610 (exon 1) 0.21 0.14 0.14 0.092
Novel c.144CT, p.48II 92,342,683 (exon 1) 0 0.008 0 –
rs6483210 Exon 2  18CT 92,354,243 (intron 1) 0.03 0.02 0.04 –
Novel c.370GA, p.124VI 92,354,407 (exon 2) 0 0.008 0 0.004
rs61746674 c.412CT, p.138RC 92,354,449 (exon 2) 0 0.02 0 0.001
rs8192553 c.692GA, p.231RH 92,354,729 (exon 2) 0 0.008 0.005 0.006
rs61747139 c.728AG, p.243KR 92,354,765 (exon 2) 0.01 0.02 0.04 0.033
Novel Exon 2  38TC 92,355,164 (3
UTR) 0 0.008 0.005 –
Novel Exon 2  107GT 92,355,233 (3
UTR 0 0 0.005 –
rs1562444 Exon 2  370GA 92,355,497 (3
UTR) 0.59 0.55 0.49 –
rs12792653 Exon 2  437GA 92,355,564 (3
UTR) 0.59 0.55 0.48 –
Novel* c.179TG, p.60LR 92,342,718 (exon 1) 0 0 0 0.00055
Variant locations are displayed as base numbers counting from the p-arm telomere of chromosome 11 (according to the UCSC Genome
Browser on Human Mar. 2006 Assembly: http://genome.ucsc.edu/cgi-bin/hgGateway). *L60R was not identiﬁed in this screening but identiﬁed
in a French population recently (ref. 2).
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decreased BMI ( 4.4 kg/m
2 [8.7 to 0.0], P  0.05) in
the Danish Inter99 population (Table 4). No signiﬁcant
associations with BMI and waist circumference were
observed in the French population–based D.E.S.I.R. co-
hort (Table 4), in the combined Danish and French anal-
yses (Table 4), or in any of the selected cohorts (online
appendix Table 7).
V124I did not associate with BMI or waist circumfer-
ence in Inter99, in the D.E.S.I.R. cohort, or in combined
Danish and French analyses (Table 4). Sporadic associ-
ations with increased BMI were found in the Danish
ADDITION screening cohort of individuals in high risk
of undiagnosed type 2 diabetes and in the French FSO
study (online appendix Table 7). R138C, R231H, and
K243R did not show any signiﬁcant association with
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TABLE 2
Danish case-control studies of type 2 diabetes for six MTNR1B variants in 3,617 case and 4,975 control individuals
Normal glucose tolerance Type 2 diabetes OR (95%CI) P
G24E (rs8192552) 4,019/831/33 2,935/598/32 1.00 (0.87–1.15) 0.97
L60R 4,891/3/0 3,548/2/0 2.58 (0.32–21.07) 0.38
V124I 4,883/35/0 3,484/30/0 1.27 (0.69–2.35) 0.44
R138C (rs61746674) 4,898/9/0 3,525/5/0 0.91 (0.23–3.63) 0.89
R231H (rs8192553) 4,853/53/1 3,498/41/0 0.98 (0.58–1.63) 0.92
K243R (rs61747139) 4,572/331/4 3,310/214/5 0.95 (0.76–1.19) 0.67
Data are presented as wildtype/heterozygous/homozygous unless otherwise indicated. ORs and P values were calculated assuming a
dominant (L60R, V124I, R138C, R231H, and K243R) or additive (G24E) genetic model adjusted for age and sex.
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population (Table 4).
Quantitative analyses of biochemical variables ob-
tained from an OGTT. Analyses of anthropometric
measurements and biochemical variables during an OGTT
were performed in the Danish population–based Inter99
(Table 5). Codon 24E associated with a decrease in FPG
(per allele  0.06 mmol/l [0.1 to 0.01], P  0.02)
(Table 5). This association was strengthened when analy-
ses were adjusted for the difference in BMI ( 0.08
mmol/l [0.13 to 0.03], P  9  10
4), but no signiﬁcant
interactions with BMI were observed (P  0.2). Condi-
tional analyses of MTNR1B intronic variant rs10830963,
previously reported to increase FPG (1–4), and rs8192552
(G24E) were performed. The linkage disequilibrium be-
tween the two variants were D
0.99, r
2  0.04 (online
appendix Table 5). After inclusion of rs10830963 in the
model, rs8192552 (G24E) still had an effect on FPG (P 
0.02) (online appendix Table 6).
Four carriers of codon 60R had decreased insulinogenic
index ( 83% [152 to 13], P  0.02) (Table 5),
which remained nominally signiﬁcant when analyses were
adjusted for the difference in BMI ( 72% [140 to
5], P  0.04).
243R was nominally associated with decreased FPG
( 0.08 mmol/l [0.16 to 0.01], P  0.04) (Table 5).
Conditional analyses of rs10830963 and rs61747139
(K243R) in linkage disequilibrium (D
0.99; r
2  0.01
were performed (online appendix Table 5). After inclusion
of rs10830963 in the model, the effect of rs61747139
(K243R) disappeared (P  0.2) (online appendix Table 6).
No associations with anthropometric or biochemical mea-
surements were observed for V124I, R138C, or R231H.
Analyses of MT2 receptor signaling. The wild-type
MT2 receptor displayed a relatively high degree of consti-
tutive signaling activity and a clear dose-related increase
in signaling in response to melatonin (Fig. 2). The dose-
response curve for melatonin in the 24E mutant form of
the MT2 receptor was similar to that of the wild-type
receptor with respect to potency and efﬁcacy; however,
the ligand-independent constitutive signaling was slightly
decreased (Fig. 2). Functional characterization of the 60R
mutant receptor revealed that both constitutive and mela-
tonin-induced signaling were completely disrupted for this
mutant (Fig. 2). The 124I mutant receptor had decreased
constitutive activity and maximal efﬁcacy compared with
the wild-type MT2 receptor.
DISCUSSION
In the present study, we found no MODY-speciﬁc muta-
tions in MTNR1B. We describe novel associations of G24E
with measures of obesity and FPG. None of the investi-
gated MTNR1B variants were associated with type 2
diabetes. Decreased MT2 Gi-coupled signaling, as ob-
served to various extents for 24E, 60R, and 124I mutant
receptors, did not correlate strongly with type 2 diabetes
or FPG.
The common 24E variant (MAF 9.2% in the Danish
population) increased the risk of obesity and BMI in
Danish and French individuals but also decreased FPG by
0.08 mmol/l per allele, as estimated in the Danish popula-
tion. Conditional analyses showed that this effect on FPG
could only be partly explained by linkage to the previously
reported intronic rs10830963 variant. An apparent paradox
is that FPG is decreased while BMI and waist circumfer-
ence are increased in carriers of 24E, and we hypothesize
that these dual ﬁndings could be due to differential regu-
lation in speciﬁc target tissues. The effect on FPG may
reﬂect the functionality of pancreatic MT2 receptors as
previously suggested for the signal obtained in the GWA
studies (4). It has also been suggested based on ﬁndings in
animal and in vitro experiments that melatonin may act on
body weight regulation through activation of central
(brain) or peripheral (gastrointestinal tract and adipocyte)
receptors (7,33), and the effect we observed on BMI might
therefore reﬂect the function of MT2 receptors in these
tissues. When the association between 24E and waist
circumference was adjusted for BMI in the Inter99 and
D.E.S.I.R. cohorts, no signiﬁcant associations were ob-
served (data not shown), pointing toward an effect of the
genotype on overall fat distribution rather than on speciﬁc
abdominal obesity. Investigations in populations with de-
tailed measures of body composition would consequently
be of interest for future studies.
G24E (rs8192552) has not been reported in large GWA
studies of obesity (34–36). The variant has not been
genotyped in HapMap, and its coverage by GWA studies is
thus unclear. It may therefore be that rs8192552 is not
adequately captured by variants analyzed in previous GWA
studies. Alternatively, heterogeneity among the investi-
gated GWA populations could be an explanation for the
lack of strongly signiﬁcant association with BMI or obesity
in these studies.
G24 is conserved in rhesus and mouse but not in
elephant, opossum, or platypus. Functionally, we observed
that the MT2 24E mutant had a somewhat decreased
TABLE 3
Case-control studies of obesity for six MTNR1B variants in Danish (up to n  6,828) and French (n  3,773) individuals
Danish French Combined (n  10,601)
Normal
weight Obesity OR (95%CI) P
Normal
weight Obesity OR (95%CI) P OR (95%CI) P
G24E* 2,365/442/17 3,168/678/33 1.21 (1.05–1.39) 0.0081 2,276/353/14 859/159/8 1.21 (1.00–1.46) 0.046 1.20 (1.08–1.34) 8.3  10
4
L60R* 2,822/3/0 3,868/1/0 0.12 (0.01–1.4) 0.091 2,708/8/0 1,019/4/0 1.29 (0.39–4.33) 0.68 0.66 (0.21–2.06) 0.48
V124I* 2,824/12/0 3,833/31/0 1.74 (0.83–3.67) 0.14 2,691/3/0 1,016/2/0 1.78 (0.29–10.81) 0.53 1.74 (0.91–3.35) 0.095
R138C 2,822/6/0 1,906/3/0 0.89 (0.21–3.82) 0.87
R231H 2,809/26/1 1,888/20/0 1.0 (0.53–1.9) 0.99
K243R 2,647/185/2 1,786/124/3 0.99 (0.77–1.27) 0.93
Data are presented as wild-type/heterozygous/homozygous unless otherwise indicated. ORs and P values were calculated assuming a
dominant (L60R, V124I, R138C, R231H, and K243R) or additive (G24E) genetic model adjusted for age and sex. Nationality has been applied
as an adjusting factor in the combined analyses. *Additional obese cases (n  1,991) were genotyped for G24E, L60R, and V124I. Normal
weight was deﬁned as BMI  25 kg/m
2. Obesity was deﬁned as BMI  30 kg/m
2.
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the wild-type receptor upon melatonin stimulation, as
observed in cells cotransfected with a promiscuous G-
protein commonly used to study signaling properties of
Gi-coupled receptors (32). The MT2 receptor is believed
to signal mainly through Gi but has been shown to be
able to activate a number of intracellular signaling path-
ways (37,38). The association of the G24E variant with
BMI and FPG observed in the present study will justify an
in-depth cell biological and molecular pharmacological
analysis of this variant in particular; such studies are,
however, hampered by lack of appropriate in vitro cell
systems that diligently reﬂect the cell biology of tissues
where MT2 is normally expressed. Nevertheless, the nor-
mal maximal signaling efﬁcacy observed for the 24E
mutant indicates that the amino acid substitution does not
lead to misfolding or lack of cell surface expression, which
otherwise is a common molecular phenotype for 7TM
receptor variants (39). Given that the 24E variant is
located in the extracellular part of the receptor, it is
plausible that receptor interactions with other ligands or
proteins may be modiﬁed by the amino acid substitution.
Finally, because the variant is common, other yet uniden-
tiﬁed regulatory variants in linkage disequilibrium could
also be responsible for the observed associations.
L60R was very rare among Danes (MAF 0.056%) where a
tendency toward decreased BMI was observed. However,
this ﬁnding could not be conﬁrmed in a French population,
although the variant had a higher frequency (MAF 0.16%)
among French individuals. In the Danish Inter99 popula-
tion, four 60R carriers had on average 83% decreased
glucose-stimulated insulin response measured by the insu-
linogenic index, but still no effect on FPG was observed. It
is an important limitation that we have very few 60R
TABLE 4
BMI and waist circumference in Danish (n  5,885) and French (n  4,626) population–based individuals stratiﬁed according to six
MTNR1B genotypes
Danish Inter99 French D.E.S.I.R. Combined (n  10,510)
N
Age
(years)
BMI
(kg/m
2) Waist (cm) N
Age
(years)
BMI
(kg/m
2) Waist (cm)
BMI
(kg/m
2) Waist (cm)
G24E (rs8192552)
Wild type 4,736 46  8 26.1  4.5 86  13 3,874 47  10 24.6  3.8 82.8  11.5
Heterozygous 995 46  8 26.6  4.7 88  13 657 46  10 25.0  4.2 84.3  12.5
Homozygous 36 45  10 27.1  5.2 86  14 26 46  8 25.4  4.3 84.4  10.8
Effect size 0.5 kg/m
2 1.1 cm 0.5 kg/m
2 1.3cm 0.5 kg/m
2 1.2 cm
95% CI 0.2 to 0.7 0.4–1.8 0.2–0.7 0.6–2.0 0.3–0.7 0.7–1.7
Padd 0.0019 0.0029 0.0011 3.7  10
4 1.2  10
5 9.4  10
6
L60R
Wild type 5,764 46  8 26.2  4.5 86  13 4,641 47  10 24.6  3.7 83.0  11.6
Heterozygous 4 48  9 21.9  3.9 80  13 15 47  10 25.0  4.1 86.9  11.0
Effect size 4.4 kg/m
2 7.1 cm 0.1 kg/m
2 0.8 cm 0.9 kg/m
2 1.0 cm
95% CI 8.7 to 0.0 18.2 to 4.1 1.8 to 2.0 4.2 to 5.9 2.8 to 1.0 6.0 to 4.0
Pdom 0.051 0.21 0.92 0.75 0.36 0.69
V124I
Wild type 5,767 46  8 26.2  4.5 87  13 4,621 47  10 24.6  3.7 83  12
Heterozygous 41 46  8 27.0  4.1 89  12 9 47  9 25.3  3.4 84  11
Effect size 0.8 kg/m
2 1.5 cm 0.8 kg/m
2 1.9 cm 0.8 kg/m
2 1.6 cm
95% CI 0.6 to 2.1 20.0 to 50.0 1.6 to 3.1 4.1 to 8.0 0.4 to 1.9 1.3 to 4.5
Pdom 0.28 0.41 0.52 0.53 0.19 0.29
R138C (rs61746674)
Wild type 5,781 46  8 26.2  4.5 87  13
Heterozygous 12 45  8 25.3  4.0 82  10
Effect size 0.9 kg/m
2 4.9 cm
95% CI 3.5 to 1.6 11.3 to 1.6
Pdom 0.47 0.14
R231H (rs8192553)
Wild type 5,733 46  8 26.2  4.5 86.5  13.2
Heterozygous 61 47  7 26.4  4.0 86.2  13.9
Homozygous 1 55 23.8 74
Effect size 0.2 kg/m
2 0.0 cm
95% CI 0.9 to 1.3 2.9 to 2.8
Pdom 0.74 1.0
K243R (rs61747139)
Wild type 5,418 46  8 26.2  4.5 86.5  13.2
Heterozygous 379 46  7 26.2  4.6 86.8  13.4
Homozygous 3 48  12 24.6  1.6 82.0  2.7
Effect size 0.0 kg/m
2 0.4 cm
95% CI 0.5 to 0.4 0.8 to 1.5
Pdom 0.89 0.55
Data are means  SD stratiﬁed according to genotypes of MTNR1B G24E, L60R, and V124I. Effect sizes and P values are calculated assuming
an additive (Padd) or dominant (Pdom) genetic model of inheritance adjusted for age and sex. Nationality has been applied as an adjusting
factor in the combined analyses.
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clude an effect of L60R, and the results obtained may be
spurious. Of particular interest, L60R changes a hydropho-
bic leucine to a positively charge arginine at position 60,
which is highly conserved as an aliphatic hydrophobic
residue (82%) in transmembrane segment 1 (TM-I) of 7TM
receptors in general (40). It is very likely that the com-
pletely eliminated signaling by substitution with the basic
arginine residue is caused by disruption of the normal
hydrophobic interaction of L60 with the intracellular helix
VIII. Although heterozygous knockdown of MT2 signaling
revealed no obvious human metabolic phenotype in this
study, prospective studies are highly relevant to evaluate
whether a phenotype evolves as a function of aging and
various environmental pressures. No homozygous muta-
tion carriers have been identiﬁed; hence, it is also possible
that one functional allele is sufﬁcient to ensure a normal
phenotype. Supporting this hypothesis, partial redundancy
between the melatonin receptor types has been suggested
(37) and both homodimer and MT1/MT2 heterodimer
formation is described in vitro, where activation of one
binding site is sufﬁcient to induce a conformational change
in the dimer (41). In addition, MT2 knockout mice have no
obvious metabolic phenotype (42,43).
The initial association between 124I and obesity ob-
served in a Danish case-control study could not be con-
ﬁrmed in combined case-control analyses or in analyses of
BMI and waist circumference as quantitative variables in
the Danish and French populations. 124I is very rare
among French individuals, severely impeding statistical
power for replication. We observed, however, an effect of
124I on BMI in the Danish ADDITION screening cohort of
individuals in high risk of type 2 diabetes, implying that
124I may increase BMI in selected high-risk groups, al-
though it has no strong effect in the general population.
V124 is conserved among mammalian species but not in
chicken, lizard, or Xenopus, and it has been proposed that
this residue is involved in the binding of melatonin (44)
The 124I mutant had impaired MT2 signaling, but because
completely disrupted signaling as observed for the 60R
mutant does not lead to increased BMI, these results do
not support the associations observed for V124I in se-
lected study populations.
We observed various degrees of decreased signaling for
the three MT2 mutants, which however, does not seem to
associate directly with type 2 diabetes or FPG. This is in
line with a recent study by Lyssenko et al. (4) suggesting
that increased MTNR1B expression in -cells may be the
pathogenic mechanism by which FPG and the risk of type
2 diabetes are increased, supported by the fact that
melatonin inhibits insulin secretion. We did, however,
observe impaired insulin release for the four 60R carriers,
and it is not known at present whether these individuals
will develop hyperglycemia or overt type 2 diabetes over
time. The associations observed for G24E may not be
ascribed to the slightly lower constitutive activity because
more severe disrupted signaling, as observed for 60R and
124I mutants, does not lead to comparable phenotypes.
The putative promoter regions of MTNR1B and poten-
tial distant regulatory regions were not targeted in the
present study, and these regions may therefore contain yet
undiscovered functional variants of importance for the
development of type 2 diabetes and related phenotypes.
Throughout this study, effects on BMI and waist circum-
ference observed in selected study samples somewhat
differed from those observed in population-based study
samples. This heterogeneity may reﬂect a true differential
effect among individual groups, statistical type II errors
due to lack of statistical power in the smaller study
samples, or statistical type I errors due to the lack of
correction for multiple testing. However, we argue that
results from large population-based studies are more
reliable in the sense that they are largely free of selection
bias, whereas results from selected study samples should
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FIG. 2. The chimeric G-protein allows the Gi-coupled receptors to
signal through the signal transduction pathways known for the Gq-
coupled receptors. Data are from Inositol turnover after stimulation
with various concentrations (conc.) of melatonin (n  3). , wild-type
(WT) MT2 receptor; f, 24E, 60R, or 124I mutant MT2 receptors. *P <
0.05 in unpaired t test.
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whether the variants have a speciﬁc effect in a certain
subpopulation of interest. When the results were adjusted
for for multiple testing (discovery samples, six SNPs and
nine independent tests; replication sample, three SNPs
and two independent tests), the associations with BMI and
waist circumference for G24E in the French D.E.S.I.R.
population and in the combined Danish and French study
samples remained signiﬁcant (P  0.05). In the present
study, the French D.E.S.I.R. population was used to eval-
uate the obesity-related discovery results obtained in the
Danish Inter99 population for G24E, L60R, and V124I. The
two populations are comparable with respect to age and
the sampling method. The MAF of L60R and V124I differed
among Danish and French individuals, implying that pop-
ulation differences across countries exist for rare variants
and thus impeding cross-population replication as a result
of drift in statistical power.
In conclusion, we ﬁnd that nonsynonymous variation in
MTNR1B is not a common cause of MODY or type 2
diabetes among Danes. MTNR1B 24E associates with
increased body mass and decreased FPG. MT2 amino acid
variants affect receptor signaling, but the observed effects
do not seem to associate strongly with FPG or type 2
diabetes.
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